Zobrazeno 1 - 10
of 144
pro vyhledávání: '"J. Knegjens"'
Autor:
Simon van Kranen, J. Knegjens, Matthew D. La Fontaine, Jeroen B. van de Kamer, Wouter V. Vogel, Jan-Jakob Sonke, N.M. Bruin
Publikováno v:
Radiotherapy and Oncology. 160:107-114
Purpose To test if the relative change in FDG-PET SUVmax over the course of treatment was associated with disease progression and overall survival. Additionally, the prognostic values of other first-order PET-metric changes were investigated. Methods
Autor:
J. Belderbos, N. Wolfhagen, J. Knegjens, J. van Diessen, P. van Rossum, null k. Smits, R. de Jong, M. Kwint, S. Clevers, R. Haas, B. Stam, T. Janssen, J.-J. Sonke, M. de Jong
Publikováno v:
Journal of Thoracic Oncology. 17:S269-S270
Autor:
Jan-Jakob Sonke, Judi N.A. van Diessen, J. Knegjens, Iris Walraven, B. Stam, José Belderbos, Margriet Kwint, Adrianus J. de Langen
Publikováno v:
Radiotherapy and Oncology, 143, 66-72
Radiotherapy and Oncology, 143, pp. 66-72
Radiotherapy and Oncology, 143, pp. 66-72
Item does not contain fulltext BACKGROUND AND PURPOSE: (Chemo)Radiotherapy for locally advanced non-small lung cancer (LA-NSCLC) causes severe dysphagia due to the radiation dose to the mediastinal lymphadenopathy. Reducing the dose to the mediastinu
Autor:
Harm van Tinteren, Kate Haslett, Astrid Keijser, Annija van der Leest, Egbert F. Smit, Bart Reymen, Matthew Hatton, Suresh Senan, Iris E. van Dam, Jos A. Stigt, Ben J. Slotman, J. Knegjens, Corinne Faivre-Finn, Devashish Tripathi, J. Praag
Publikováno v:
Lung Cancer, 108, 150-153. ELSEVIER IRELAND LTD
Lung Cancer, 108, 150-153. Elsevier Ireland Ltd
Slotman, B J, Faivre-Finn, C, van Tinteren, H, Keijser, A, Praag, J, Knegjens, J, Hatton, M, van Dam, I, van der Leest, A, Reymen, B, Stigt, J, Haslett, K, Tripathi, D, Smit, E F & Senan, S 2017, ' Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy : A secondary analysis of the Phase III CREST trial ', Lung Cancer, vol. 108, pp. 150-153 . https://doi.org/10.1016/j.lungcan.2017.03.007
Slotman, B J, Faivre-Finn, C, van Tinteren, H, Keijser, A, Praag, J O, Knegjens, J, Hatton, M, van Dam, I, van der Leest, A, Reymen, B, Stigt, J A, Haslett, K, Tripathi, D, Smit, E F & Senan, S 2017, ' Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy : A secondary analysis of the Phase III CREST trial ', Lung Cancer, vol. 108, pp. 150–153 . https://doi.org/10.1016/j.lungcan.2017.03.007
Lung Cancer, 108, 150-153. Elsevier Ireland Ltd
Slotman, B J, Faivre-Finn, C, van Tinteren, H, Keijser, A, Praag, J, Knegjens, J, Hatton, M, van Dam, I, van der Leest, A, Reymen, B, Stigt, J, Haslett, K, Tripathi, D, Smit, E F & Senan, S 2017, ' Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy : A secondary analysis of the Phase III CREST trial ', Lung Cancer, vol. 108, pp. 150-153 . https://doi.org/10.1016/j.lungcan.2017.03.007
Slotman, B J, Faivre-Finn, C, van Tinteren, H, Keijser, A, Praag, J O, Knegjens, J, Hatton, M, van Dam, I, van der Leest, A, Reymen, B, Stigt, J A, Haslett, K, Tripathi, D, Smit, E F & Senan, S 2017, ' Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy : A secondary analysis of the Phase III CREST trial ', Lung Cancer, vol. 108, pp. 150–153 . https://doi.org/10.1016/j.lungcan.2017.03.007
Introduction: In ES-SCLC patients with residual intrathoracic disease after first-line chemotherapy, the addition of thoracic radiotherapy reduces the risk of intrathoracic recurrence, and improves 2-year survival. To identify patient subgroups for f
Publikováno v:
Radiotherapy and Oncology. 152:S225
Autor:
José Belderbos, Houke M. Klomp, Marcel Verheij, Koen J. Hartemink, Margriet Kwint, J. Knegjens, Sjaak Burgers, Iris Walraven
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 112
Objectives Patients with stage IV non-small cell lung cancer (NSCLC) are considered incurable and are mainly treated with palliative intent. This patient group has a poor overall survival (OS) and progression free survival (PFS). The purpose of this
Autor:
Wouter V. Vogel, J.J. Sonke, J. Van de Kamer, M. La Fontaine, J. Knegjens, S. Van Kranen, N.M. Bruin, José Belderbos
Publikováno v:
Radiotherapy and Oncology. 127:S94-S95
Autor:
José Belderbos, Michel M. van den Heuvel, Erik van Werkhoven, Paul Baas, Claudia Baas, Chris Rikers, J. Knegjens, Arthur Smit, Wilma Uyterlinde
Publikováno v:
Clinical Lung Cancer. 14:541-548
Background Intensity modulated radiotherapy (IMRT) is increasingly used with concurrent chemotherapy but toxicity data are not well investigated. We correlated clinical and dosimetric parameters with acute toxicity grade ≥ 3 in patients with locall
Autor:
Neshatpour, Siavash1 (AUTHOR) s.neshatpour@ip2i.in2p3.fr
Publikováno v:
Symmetry (20738994). Aug2024, Vol. 16 Issue 8, p946. 13p.
Autor:
J. Knegjens, J. Van de Kamer, J.J. Sonke, José Belderbos, N.M. Bruin, M. van Herk, Wouter V. Vogel
Publikováno v:
Radiotherapy and Oncology. 115